North America Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity

November 2023 | 132 pages | ID: N6EA2E5BE201EN
GMD Research

Abstracts

North America preventive vaccines market is projected to grow by 6.3% annually in the forecast period and reach $46.90 billion by 2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure.

Highlighted with 52 tables and 51 figures, this 132-page report “North America Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.

Based on Vaccine Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• mRNA Vaccines
• Recombinant Vector Vaccines
• Other Vaccines

Based on Disease, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Pneumococcal Disease
• Poliovirus
• Hepatitis
• Influenza
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Human Papilloma Virus
• COVID-19
• Other Diseases

By Administration, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes

By Patient, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Pediatric Vaccines
• Pneumococcal
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Hepatitis
• Poliovirus
• Haemophilus Influenzae B (HIB)
• Other Diseases
• Adult Vaccines
• Influenza
• Cervical Cancer
• Hepatitis
• Zoster
• Other Diseases

Geographically, the following national/local markets are fully investigated:

• U.S.
• Canada
• Mexico

For each key country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Vaccine Type, Disease, and Administration over the forecast years are also included.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Selected Key Players:

AstraZeneca plc

Bavarian Nordic A/S

China National Biotec Group Company Ltd.

CSL Ltd.

Daiichi Sankyo Co. Ltd

Emergent BioSolutions Inc.

GlaxoSmithKline plc

Johnson & Johnson

Merck & Co.

Moderna Inc.

Novavax, Inc.

Pfizer Inc.

Sanofi SA

Takeda Pharmaceutical Co. Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on World Economy
  2.1.2 Impact of COVID-19 on the Market
  2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF NORTH AMERICA MARKET BY VACCINE TYPE

3.1 Market Overview by Vaccine Type
3.2 Live/Attenuated Vaccines
3.3 Inactivated Vaccines
3.4 Subunit Vaccines
3.5 Toxoid Vaccines
3.6 Conjugate Vaccines
3.7 mRNA Vaccines
3.8 Recombinant Vector Vaccines
3.9 Other Vaccines

4 SEGMENTATION OF NORTH AMERICA MARKET BY DISEASE

4.1 Market Overview by Disease
4.2 Pneumococcal Disease
4.3 Poliovirus
4.4 Hepatitis
4.5 Influenza
4.6 Measles, Mumps, and Rubella (MMR)
4.7 Varicella
4.8 Human Papilloma Virus
4.9 COVID-19
4.10 Other Diseases

5 SEGMENTATION OF NORTH AMERICA MARKET BY ADMINISTRATION

5.1 Market Overview by Administration
5.2 Intramuscular Route
5.3 Subcutaneous Route
5.4 Oral Route
5.5 Intravenous Injection
5.6 Other Administration Routes

6 SEGMENTATION OF NORTH AMERICA MARKET BY PATIENT

6.1 Market Overview by Patient
6.2 Pediatric Vaccines
6.3 Adult Vaccines

7 NORTH AMERICA MARKET 2022-2032 BY COUNTRY

7.1 Overview of North America Market
7.2 U.S.
7.3 Canada
7.4 Mexico

8 COMPETITIVE LANDSCAPE

8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
RELATED REPORTS

List Of Tables

LIST OF TABLES

Table 1. Snapshot of North America Preventive Vaccines Market in Balanced Perspective, 2022-2032
Table 2. World Economic Outlook, 2021-2031
Table 3. World Economic Outlook, 2021-2023
Table 4. Scenarios for Economic Impact of Ukraine Crisis
Table 5. World Health Spending by Region, $ bn, 2013-2020
Table 6. Main Product Trends and Market Opportunities in North America Preventive Vaccines Market
Table 7. North America Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn
Table 8. North America Preventive Vaccines Market by Disease, 2022-2032, $ mn
Table 9. North America Preventive Vaccines Market by Administration, 2022-2032, $ mn
Table 10. North America Preventive Vaccines Market by Patient, 2022-2032, $ mn
Table 11. North America Preventive Vaccines Market: Pediatric Vaccines by Disease, 2022-2032, $ mn
Table 12. North America Preventive Vaccines Market: Adult Vaccines by Disease, 2022-2032, $ mn
Table 13. North America Preventive Vaccines Market by Country, 2022-2032, $ mn
Table 14. U.S. Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn
Table 15. U.S. Preventive Vaccines Market by Disease, 2022-2032, $ mn
Table 16. U.S. Preventive Vaccines Market by Administration, 2022-2032, $ mn
Table 17. Canada Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn
Table 18. Canada Preventive Vaccines Market by Disease, 2022-2032, $ mn
Table 19. Canada Preventive Vaccines Market by Administration, 2022-2032, $ mn
Table 20. Mexico Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn
Table 21. Mexico Preventive Vaccines Market by Disease, 2022-2032, $ mn
Table 22. Mexico Preventive Vaccines Market by Administration, 2022-2032, $ mn
Table 23. AstraZeneca plc: Company Snapshot
Table 24. AstraZeneca plc: Business Segmentation
Table 25. AstraZeneca plc: Product Portfolio
Table 26. Bavarian Nordic A/S: Company Snapshot
Table 27. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020
Table 28. China National Biotec Group Company Ltd.: Company Snapshot
Table 29. CSL Ltd.: Company Snapshot
Table 30. Daiichi Sankyo Co. Ltd.: Company Snapshot
Table 31. Emergent BioSolutions Inc.: Company Snapshot
Table 32. GlaxoSmithKline: Company Snapshot
Table 33. GlaxoSmithKline: Business Segmentation
Table 34. GlaxoSmithKline: Product Portfolio
Table 35. GlaxoSmithKline: Revenue, 2018-2020, $ bn
Table 36. GlaxoSmithKline: Recent Developments
Table 37. Johnson & Johnson: Company Snapshot
Table 38. Johnson & Johnson: Business Segments
Table 39. Merck & Co., Inc.: Company Snapshot
Table 40. Merck & Co., Inc.: Business Segmentation
Table 41. Merck & Co., Inc.: Revenue, 2018-2020, $ bn
Table 42. Moderna Inc.: Company Snapshot
Table 43. Novavax, Inc.: Company Snapshot
Table 44. Pfizer Inc.: Company Snapshot
Table 45. Pfizer Inc.: Business Segmentation
Table 46. Pfizer Inc.: Product Portfolio
Table 47. Pfizer Inc.: Revenue, 2018-2020, $ bn
Table 48. Pfizer Inc.: Recent Developments
Table 49. Sanofi: Company Snapshot
Table 50. Sanofi: Business Segmentation
Table 51. Sanofi: Revenue, 2018-2020, $ bn
Table 52. Takeda Pharmaceutical Co. Ltd.: Company Snapshot

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032
Figure 4. North America Preventive Vaccines Market, 2022-2032, $ mn
Figure 5. Development Stages of Preventive Vaccines
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of North America Preventive Vaccines Market
Figure 8. Leading Causes of Death in the World, 2000 and 2019, million
Figure 9. Worldwide Geriatric Population (60 years and above) by Region, 2015 & 2030, million
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060
Figure 11. Primary Restraints and Impact Factors of North America Preventive Vaccines Market
Figure 12. Investment Opportunity Analysis
Figure 13. Porter’s Fiver Forces Analysis of North America Preventive Vaccines Market
Figure 14. Breakdown of North America Preventive Vaccines Market by Vaccine Type, 2022-2032, % of Revenue
Figure 15. North America Addressable Market Cap in 2023-2032 by Vaccine Type, Value ($ mn) and Share (%)
Figure 16. North America Preventive Vaccines Market by Vaccine Type: Live/Attenuated Vaccines, 2022-2032, $ mn
Figure 17. North America Preventive Vaccines Market by Vaccine Type: Inactivated Vaccines, 2022-2032, $ mn
Figure 18. North America Preventive Vaccines Market by Vaccine Type: Subunit Vaccines, 2022-2032, $ mn
Figure 19. North America Preventive Vaccines Market by Vaccine Type: Toxoid Vaccines, 2022-2032, $ mn
Figure 20. North America Preventive Vaccines Market by Vaccine Type: Conjugate Vaccines, 2022-2032, $ mn
Figure 21. North America Preventive Vaccines Market by Vaccine Type: mRNA Vaccines, 2022-2032, $ mn
Figure 22. North America Preventive Vaccines Market by Vaccine Type: Recombinant Vector Vaccines, 2022-2032, $ mn
Figure 23. North America Preventive Vaccines Market by Vaccine Type: Other Vaccines, 2022-2032, $ mn
Figure 24. Breakdown of North America Preventive Vaccines Market by Disease, 2022-2032, % of Sales Revenue
Figure 25. North America Addressable Market Cap in 2023-2032 by Disease, Value ($ mn) and Share (%)
Figure 26. North America Preventive Vaccines Market by Disease: Pneumococcal Disease, 2022-2032, $ mn
Figure 27. North America Preventive Vaccines Market by Disease: Poliovirus, 2022-2032, $ mn
Figure 28. North America Preventive Vaccines Market by Disease: Hepatitis, 2022-2032, $ mn
Figure 29. North America Preventive Vaccines Market by Disease: Influenza, 2022-2032, $ mn
Figure 30. North America Preventive Vaccines Market by Disease: Measles, Mumps, and Rubella (MMR), 2022-2032, $ mn
Figure 31. North America Preventive Vaccines Market by Disease: Varicella, 2022-2032, $ mn
Figure 32. North America Preventive Vaccines Market by Disease: Human Papilloma Virus, 2022-2032, $ mn
Figure 33. North America Preventive Vaccines Market by Disease: COVID-19, 2022-2032, $ mn
Figure 34. North America Preventive Vaccines Market by Disease: Other Diseases, 2022-2032, $ mn
Figure 35. Breakdown of North America Preventive Vaccines Market by Administration, 2022-2032, % of Sales Revenue
Figure 36. North America Addressable Market Cap in 2023-2032 by Administration, Value ($ mn) and Share (%)
Figure 37. North America Preventive Vaccines Market by Administration: Intramuscular Route, 2022-2032, $ mn
Figure 38. North America Preventive Vaccines Market by Administration: Subcutaneous Route, 2022-2032, $ mn
Figure 39. North America Preventive Vaccines Market by Administration: Oral Route, 2022-2032, $ mn
Figure 40. North America Preventive Vaccines Market by Administration: Intravenous Injection, 2022-2032, $ mn
Figure 41. North America Preventive Vaccines Market by Administration: Other Administration Routes, 2022-2032, $ mn
Figure 42. Breakdown of North America Preventive Vaccines Market by Patient, 2022-2032, % of Revenue
Figure 43. North America Addressable Market Cap in 2023-2032 by Patient, Value ($ mn) and Share (%)
Figure 44. North America Preventive Vaccines Market by Patient: Pediatric Vaccines, 2022-2032, $ mn
Figure 45. North America Preventive Vaccines Market by Patient: Adult Vaccines, 2022-2032, $ mn
Figure 46. Breakdown of North America Preventive Vaccines Market by Country, 2022 and 2032, % of Revenue
Figure 47. Contribution to North America 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 48. U.S. Preventive Vaccines Market, 2022-2032, $ mn
Figure 49. Canada Preventive Vaccines Market, 2022-2032, $ mn
Figure 50. Preventive Vaccines Market in Mexico, 2022-2032, $ mn
Figure 51. Growth Stage of North America Preventive Vaccines Industry over the Forecast Period